Jane Street’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.02M | Buy |
1,456,674
+765,090
| +111% | +$1.05M | ﹤0.01% | 5074 |
|
|
2025
Q4 | $1.11M | Buy |
691,584
+540,799
| +359% | +$1.13M | ﹤0.01% | 5901 |
|
|
2025
Q3 | $412K | Buy |
+150,785
| New | +$502K | ﹤0.01% | 8266 |
|
|
2025
Q2 | – | Sell |
-173,431
| Closed | -$477K | – | 9521 |
|
|
2025
Q1 | $333K | Sell |
173,431
-28,844
| -14% | -$58.9K | ﹤0.01% | 7624 |
|
|
2024
Q4 | $384K | Buy |
202,275
+78,547
| +63% | +$136K | ﹤0.01% | 7303 |
|
|
2024
Q3 | $163K | Sell |
123,728
-2,766
| -2% | -$3.69K | ﹤0.01% | 8774 |
|
|
2024
Q2 | $129K | Sell |
126,494
-271,566
| -68% | -$336K | ﹤0.01% | 8633 |
|
|
2024
Q1 | $728K | Buy |
398,060
+300,517
| +308% | +$480K | ﹤0.01% | 6009 |
|
|
2023
Q4 | $121K | Buy |
97,543
+37,372
| +62% | +$38.1K | ﹤0.01% | 8499 |
|
|
2023
Q3 | $68.6K | Buy |
60,171
+3,060
| +5% | +$3.93K | ﹤0.01% | 8075 |
|
|
2023
Q2 | $52.3K | Buy |
57,111
+10,918
| +24% | +$10.5K | ﹤0.01% | 8199 |
|
|
2023
Q1 | $25.9K | Sell |
46,193
-477,510
| -91% | -$365K | ﹤0.01% | 8597 |
|
|
2022
Q4 | $302K | Buy |
523,703
+513,064
| +4,822% | +$161K | ﹤0.01% | 7009 |
|
|
2022
Q3 | $3K | Sell |
10,639
-151,527
| -93% | -$59.5K | ﹤0.01% | 9488 |
|
|
2022
Q2 | $57K | Sell |
162,166
-388,481
| -71% | -$163K | ﹤0.01% | 8887 |
|
|
2022
Q1 | $395K | Buy |
550,647
+263,945
| +92% | +$565K | ﹤0.01% | 7904 |
|
|
2021
Q4 | $648K | Buy |
286,702
+122,037
| +74% | +$333K | ﹤0.01% | 6776 |
|
|
2021
Q3 | $474K | Buy |
164,665
+88,366
| +116% | +$252K | ﹤0.01% | 7376 |
|
|
2021
Q2 | $289K | Buy |
76,299
+43,740
| +134% | +$147K | ﹤0.01% | 8208 |
|
|
2021
Q1 | $110K | Sell |
32,559
-44,083
| -58% | -$159K | ﹤0.01% | 8598 |
|
|
2020
Q4 | $215K | Sell |
76,642
-33,879
| -31% | -$98.9K | ﹤0.01% | 6859 |
|
|
2020
Q3 | $277K | Buy |
110,521
+73,608
| +199% | +$646K | ﹤0.01% | 5991 |
|
|
2020
Q2 | $501K | Buy |
36,913
+21,390
| +138% | +$221K | ﹤0.01% | 5083 |
|
|
2020
Q1 | $118K | Buy |
15,523
+4,280
| +38% | +$33.3K | ﹤0.01% | 4880 |
|
|
2019
Q4 | $71K | Sell |
11,243
-20,953
| -65% | -$99.6K | ﹤0.01% | 4879 |
|
|
2019
Q3 | $126K | Sell |
32,196
-84,991
| -73% | -$364K | ﹤0.01% | 4760 |
|
|
2019
Q2 | $567K | Buy |
+117,187
| New | +$667K | ﹤0.01% | 3411 |
|
|
2019
Q1 | – | Sell |
-10,268
| Closed | -$57K | – | 4947 |
|
|
2018
Q4 | $57K | Buy |
+10,268
| New | +$80.4K | ﹤0.01% | 4715 |
|
|
2018
Q2 | – | Sell |
-10,024
| Closed | -$96K | – | 4913 |
|
|
2018
Q1 | $96K | Buy |
+10,024
| New | +$140K | ﹤0.01% | 4609 |
|
|
2017
Q3 | – | Sell |
-26,186
| Closed | -$376K | – | 4387 |
|
|
2017
Q2 | $376K | Buy |
+26,186
| New | +$332K | ﹤0.01% | 3363 |
|
|
2016
Q2 | – | Sell |
-13,410
| Closed | -$121K | – | 4012 |
|
|
2016
Q1 | $121K | Buy |
+13,410
| New | +$109K | ﹤0.01% | 3842 |
|
|
2015
Q3 | – | Sell |
-12,915
| Closed | -$133K | – | 3520 |
|
|
2015
Q2 | $133K | Buy |
+12,915
| New | +$110K | ﹤0.01% | 3369 |
|
|
2014
Q3 | – | Sell |
-11,000
| Closed | -$306K | – | 2497 |
|
|
2014
Q2 | $306K | Buy |
+11,000
| New | +$265K | ﹤0.01% | 1823 |
|
Other funds holding AKBA
VCM
VPM
Jane Street's AKBA Position: Q1 2026 in Review
Jane Street increased its Akebia Therapeutics (AKBA) stake by 111% in Q1 2026, buying an estimated $1.05M and bringing the position to 1,456,674 shares worth $2.02M. The position accounts for ﹤0.01% of the portfolio, ranked #5074.
Jane Street first reported a position in AKBA in Q2 2014 and has held it in 33 quarters since. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.
- Jane Street held 1,456,674 shares of Akebia Therapeutics worth $2.02M as of Q1 2026.
- Jane Street bought 765,090 Akebia Therapeutics shares in Q1 2026, an estimated $1.05M.
- Akebia Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #5074 holding.
- Jane Street first reported a position in Akebia Therapeutics in Q2 2014 and has held it in 33 quarters since.
- 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.
Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.